Multiple sclerosis

Week in Review: At-home flu testing, asymptomatic monkeypox, telediagnostic accuracy, and more

By Leo O'Connor

Dear LabPulse.com member,

September 7, 2022

NfL IDs patients predisposed to neurotoxic complications

By LabPulse.com staff writers

Analyzing blood samples from patients before, during, and after CAR-T cell therapy, Washington University School of Medicine researchers found that levels of neurofilament light chain (NfL) proteins are higher in patients who develop neurotoxic complications.

August 31, 2022

3M divides health, oral care division into new business

Its new standalone healthcare business will focus on oral care, wound care, healthcare information technology, and biopharma filtration. The tax-free transaction is expected to close by the end of 2023. 3M's healthcare sector generated approximately $8.6 billion in sales in 2021, according to the company.

July 27, 2022

Drug test detects possibly toxic cannabis derivative

By LabPulse.com staff writers

Breaking research showcased on Tuesday at AACC 2022 demonstrates that common drug testing methods can do just that.

July 26, 2022

Labcorp NfL test confirms neurodegenerative disease

By LabPulse.com staff writers

The neurofilament light chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients, the firm said.

July 12, 2022

Quanterix secures breakthrough device designation for MS test

By LabPulse.com staff writers

Simoa measures NfL in human serum and plasma and is intended to help identify patients with relapsing-remitting MS who are at risk of relapse within four years. The designation comes after a study published March 1 in The Lancet Neurology described the effective use of Simoa to interpret elevated NfL values in MS patients, the company said.

April 24, 2022

Lifespin establishes division in the U.S.

By LabPulse.com staff writers

Lifespin is a deep learning company that is building a diagnostic testing platform based on metabolomics. The company's U.S. subsidiary is incorporated in Delaware and initially based in Boston. Dr. Ali Tinazli, the president and CEO of Lifespin, and Dr. Trevor Hawkins, a Lifespin board member, will lead the operations in the U.S.

April 13, 2022

Siemens' MS assay receives FDA breakthrough designation

By LabPulse.com staff writers

The assay quantitatively measures neurofilament light (NfL), a biomarker for nerve cell injury, in cerebrospinal fluid and blood. It is intended to be used in conjunction with clinical, imaging, and laboratory findings. The assay is designed to help identify adult patients with relapsing MS who are considered lower risk of disease activity.

March 24, 2022

Agilent acquires Virtual Control's lab AI technology

By LabPulse.com staff writers

Specifically, ACIES will be used with liquid chromatography/mass spectrometry (LC/MS) and gas chromatography and MS (GS/MS) instruments. It automates the labor-intensive task of GS/MS data analysis, improving efficiency in the laboratory workflow from sampling to reporting, Agilent said.

February 16, 2022

BrainChip, NaNose laud progress in breath sample COVID-19 test

By LabPulse.com staff writers

The test incorporates NaNose Medical's sensor array to collect data and BrainChip's Akida artificial intelligence chip to perform the diagnosis, according to the two firms. NaNose's sensory array is based on technology developed at Technion Israel Institute of Technology in Haifa, and has similar sensitivity to minute quantities of volatile organic compounds (VOCs) as a dog's nose.

February 24, 2021

Man's best friend helps train neural network for prostate cancer

By Joseph Constance

Researchers with Medical Detection Dogs of the U.K. studied the olfactory ability of dogs to detect aggressive prostate cancer from urine samples and used it to train an artificial neural network (ANN) to better detect cancer in diagnostics. They found that the cancer-sniffing ability of the canines was just one of several factors that could be used to optimize their neural network.

February 17, 2021

LabLynx debuts LIMS for COVID-19 testing

By LabPulse.com staff writers

CovidLiMS is a low-cost, turnkey LIMS that can go from setup to live within two to five days, according to the company. The system addresses the needs of existing clients and labs that need to perform COVID-19 testing but don't have a LIMS, or software suitable for COVID-19 testing, LabLynx said.

April 9, 2020

Page 1 of 2

Next Page